Medtronic, the world's largest medical device maker, said Monday it received U.S. regulatory approval for an implant to prevent stroke caused by ruptures of the aortic artery.
The Food and Drug Administration approved the company's Talent Thoracic Stent Graft to treat dangerous bulges of the body's main artery, which can rupture, potentially causing death.
About 60,000 in the U.S. are estimated to have the condition, though only half are ever diagnosed, according to the company.
Medtronic markets hundreds of medical implants, including pacemakers, defibrillators and stents.
Company shares fell 7 cents Monday to close at $35.16.